More cancer and HIV drugs added to Australian PBS
More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits Scheme (PBS) from this month, including people being treated for cancer, HIV and chronic obstructive pulmonary disease, the government has announced.
Minister for Health and Ageing Nicola Roxon explained that the changes include the listing of denosumab (US biotech firm Amgen’s Xgeva), which will help about 4,000 people with breast or prostate cancer-related bone metastases who also have severe kidney function problems, or who undergo dialysis treatment.
Between 65% and 75% of patients with advanced breast or prostate cancer develop bone metastases, which involve the spread of cancer cells. Complications of bone metastases include severe pain, fractures and spinal cord compression - which all have the potential to significantly reduce a patient’s quality of life and independence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze